Bharat Biotech to pay compensation if Covaxin causes side effects

The government has procured 55 million doses of Covaxin, apart from 110 million of Covishield by the Serum Institute of India.

Published: 16th January 2021 03:09 PM  |   Last Updated: 17th January 2021 08:12 AM   |  A+A-


A health official shows a Covaxin vaccine dose after a consignment of the vaccine arrived at Kalawati Saran hospital in New Delhi. (Photo | Shekhar Yadav, EPS)

Express News Service

NEW DELHI: The  consent forms, signing which has been made a must for people receiving Covaxin at vaccination centres makes it clear that Bharat Biotech will be liable for paying compensation in case of serious adverse events following immunisation but does not mention compensation amount. The form has been attached to the vaccine — still to prove its efficacy in protecting from SARS CoV 2- as it has been launched on a “clinical trial mode”, as mandated by the Drug Controller General of India.

The government has procured 55 million doses of Covaxin, apart from 110 million of Covishield by the Serum Institute of India, for the first phase of the nationwide Covid-19 vaccination drive but there are reports of concern among doctors, hesitant to go for a vaccine still under trial. In several states, like in Delhi, Covaxin is being offered only in Centrally run hospitals and healthcare workers are not being given a choice in opting for a vaccine they want.

Sources in the health ministry and the ICMR said that beneficiaries receiving Covaxin are required to sign a consent form, which assures medical care and compensation if any adverse effect was found linked to the vaccine. “In phase 1 and phase 2 clinical trials, Covaxin has demonstrated the ability to produce antibodies against Covid-19,” says the form. “However, Covaxin ‘s clinical efficacy is yet to be established and it is still being studied in phase 3 clinical trials.

Hence, it is important to appreciate that receiving the vaccine does not mean that other precautions need not be followed.” The form further says, “In case of any serious adverse events, vaccine recipients will be provided medically recognized standard of care in the government designated and authorized centers/hospitals. The compensation for the serious adverse event will be paid by sponsor (BBIL) if the SAE is proven to be causally related to the vaccine.”

Adding that the compensation will be determined by the ICMR Central Ethics Committee. Doctors, experts and bioethicists have questioned the restricted emergency use approval granted to Covaxin despite incomplete trial. Charges of unethical enrolment of participants for the phase 3 clinical trial of the vaccine in Bhopal—one of whom even died, even though it was ruled out that the event was related to Covaxin administration— has further eroded trust in the partially tested vaccine.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp